Pay in 4 interest-free payments of $6.85 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
When gastric emptying slows, oral medications may take longer to reach the small intestine, where most absorption occurs
July 23-24, 2026 FDA meeting: The Pharmacy Compounding Advisory Committee will formally review BPC-157 (free base and acetate salt), KPV, TB-500, and MOTS-c at the FDA White Oak Campus
Survodutide (BI 456906) is a GLP-1/glucagon co-agonist which has progressed to phase 3 clinical trials as treatment for obesity (SYNCHRONIZE programme)
Occasional mild injection-site reactions
Diabetes - GLP-1 agonists should be primarily considered in patients with type 2 diabetes with suboptimal glycaemic control despite maximal tolerated dose of metformin (+/- other agents) especially where weight loss is desired and/or significant stroke risk is present
